http://rdf.ncbi.nlm.nih.gov/pubchem/reference/29816181

Outgoing Links

Predicate Object
contentType Case Reports|Journal Article
endingPage 5009
issn 2224-5839
2224-5820
issueIdentifier 4
pageRange 4999-5009
publicationName Annals of Palliative Medicine
startingPage 4999
bibliographicCitation Ni J, Yang L, Zhu H, Chu M, Zhang C, Zhao W, Yang M, Xu X, Zheng E, Jiang X, Li R, Zhao G. A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: a case report. Ann Palliat Med. 2021 Apr;10(4):4999–5009. doi: 10.21037/apm-21-860. PMID: 33966436.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_767295d5fee9961f9e0f456d93af0ff6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ca00dbe1eabc076cda6f428310224a5
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_39080ff3a77c43ecb54d182928cf3f7f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_07a0e1ef3683ef0dbc2c5f7f71cd8cff
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_32d12cb71f670592ac3aaed7b310a275
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c786d1a54c6fc58b7c709213353d00f6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_fe46533066492b88e41d61bc269ae645
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c3022570f0bed0a8a7970fef8f8bf725
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3724a828fb3003a85439c1216b51a89f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b873b8bf059e6780229b77773616e981
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c96524cc128b066ea1cb24d311af079a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-6809-0837
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1bc892fd7d9529e027cf83afff19721c
date 202104
identifier https://doi.org/10.21037/apm-21-860
https://pubmed.ncbi.nlm.nih.gov/33966436
isPartOf https://portal.issn.org/resource/ISSN/2224-5839
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/40347
https://portal.issn.org/resource/ISSN/2224-5820
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title A patient with metastatic non-small cell lung cancer who received pembrolizumab monotherapy after stereotactic body radiotherapy had progression-free survival of nearly 5 years: a case report
discusses http://id.nlm.nih.gov/mesh/M0556300
http://id.nlm.nih.gov/mesh/M0586473
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D002289Q000532
http://id.nlm.nih.gov/mesh/D002289Q000188
http://id.nlm.nih.gov/mesh/D016634
http://id.nlm.nih.gov/mesh/D008175Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D000077982
http://id.nlm.nih.gov/mesh/D002681
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D061067
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8366
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168

Total number of triples: 46.